Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147119 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL147120 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL6440343 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL38558 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL288384 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL5980144 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL38557 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL1468176 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL16635360 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 | |
| SCHEMBL1468174 | 0.98 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4NPSR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | claimed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| CN-101535336-A | Synthetic phthalamides and dimers thereof | SYNTHETIC PEPTIDE AMIDES AND D (US) | 2009-09-16 | — | — | CN | claimed |
| EP-2079756-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | Cara Therapeutics, Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2008060552-A2 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF | CARA THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | disclosed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| EP-4433495-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2024-09-25 | — | — | EP | disclosed |
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
| CN-112739366-B | Oral formulations of kappa opioid receptor agonists | 卡拉治疗学股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | disclosed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| EP-0922054-B1 | ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES | GYOGYSZERKUTATO INTEZET (HU) | 2002-08-14 | — | — | EP | disclosed |
| EP-0922054-A1 | ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES | GYOGYSZERKUTATO INTEZET KFT. (HU) | 1999-06-16 | — | — | EP | disclosed |
| WO-1997046576-A1 | ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES | Gyógyszerkutató Intézet Kft. (HU) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | OPRL1, OPRK1, OPRM1 | SMN1; SMN2 281/4885ALDH1A1 4191/4885CYP3A4 3841/4885 |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | SMN1; SMN2 1196/4885ALDH1A1 2052/4885CYP3A4 2493/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | SMN1; SMN2 1196/4885ALDH1A1 2052/4885CYP3A4 2493/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | SMN1; SMN2 3709/4885ALDH1A1 3381/4885CYP3A4 69/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | SMN1; SMN2 3272/4885ALDH1A1 3387/4885CYP3A4 127/4885 |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | SMN1; SMN2 3272/4885ALDH1A1 3387/4885CYP3A4 127/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | SMN1; SMN2 315/4885ALDH1A1 3511/4885CYP3A4 2793/4885 |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | SMN1; SMN2 4751/4885ALDH1A1 468/4885CYP3A4 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.